Cooley LLP is a market leader in life sciences and technology offerings, including for a growing number of European, Asian and Latin American issuers. A new office in Miami has increased its connection to the Latin American market. In 2023, it continued to work on a series of IPOs and follow-on offerings by issuers in Europe and Asia. The firm has a wide-ranging and impressive client base from start-ups to growth businesses and established public companies. It is also close to key financial institutions. A force in equity offerings, it has a further presence in equity-linked transactions. San Diego-based Charlie Kim heads the capital markets team alongside David Peinsipp in San Francisco. New York’s Div Gupta and Richard Segal are also leading names.
Legal 500 redaktioneller Kommentar

Kernmandanten

  • Abivax S.A.
  • Addex Therapeutics SA
  • Ambrx Biopharma
  • Autolus Therapeutics plc
  • Bicycle Therapeutics plc
  • Cowen and Company
  • Exscientia plc
  • Faron Pharmaceuticals Oy
  • Gamida Cell Ltd.
  • Goldman Sachs & Co. LLC

Highlight-Mandate

  • Advised the underwriters on argenx SE’s $1.2bn follow-on offering.
  • Represented Abivax in its $235.8m IPO.
  • Advised Structure Therapeutics on its $185.3m IPO.

Anwält*innen

Praxisleitung

Charlie Kim; David Peinsipp

Weitere Kernanwält*innen

Richard Segal; Div Gupta